The Impella Microaxial Flow Catheter Is Safe and Effective for Treatment of Myocarditis Complicated by Cardiogenic Shock: An Analysis From the Global cVAD Registry
Annamalai SK, Esposito ML, Jorde L, Schreiber T, Hall S, O'Neill WW, Kapur NK. The impella micro-axial flow catheter is safe and effective for treatment of myocarditis complicated by cardiogenic shock: An analysis from the global cvad registry. J Card Fail.
Journal of cardiac failure
BACKGROUND: Myocarditis complicated by cardiogenic shock remains a complex problem. The use of acute mechanical circulatory support devices for cardiogenic shock is growing. We explored the utility of Impella transvalvular microaxial flow catheters in the setting of myocarditis with cardiogenic shock.
METHODS AND RESULTS: We retrospectively analyzed data from 21 sites within the cVAD registry, an ongoing multicenter voluntary registry at sites in North America and Europe that have used Impella in patients with myocarditis. Myocarditis was defined by endomyocardial biopsy (n = 11) or by clinical history without angiographic evidence of coronary disease (n = 23). A total of 34 patients received an Impella 2.5, CP, 5.0, or RP device for cardiogenic shock complicating myocarditis. Baseline characteristics included age 42 ± 17 years, left ventricular ejection fraction (LVEF) 18% ± 10%, cardiac index 1.82 ± 0.46 L·min
CONCLUSIONS: This is the largest analysis of Impella-supported myocarditis cases to date. The use of Impella appears to be safe and effective in the settings of myocarditis complicated by cardiogenic shock.
Medical Subject Headings
Adult; Cardiac Catheters; Equipment Design; Female; Follow-Up Studies; Heart-Assist Devices; Humans; Male; Myocarditis; Registries; Retrospective Studies; Shock, Cardiogenic; Stroke Volume; Treatment Outcome